Approximately 30% of the total dose of local anaesthetic used for i.v. regional anaesthesia (IVRA) is flushed into the systemic circulation when the tourniquet is released [1] , and mild central nervous system (CNS) toxic symptoms often ensue. As a rule, non-protein bound (free) concentrations of drugs in plasma relate more closely to pharmacological and toxic effects than do total (bound plus free) concentrations [2] . Different drugs may influence the degree of protein binding of local anaesthetics and thereby affect the ratio between free and protein bound drug [3, 4] . On the other hand, the degree of CNS depression by a premedicant drug may affect the subjective perception of toxic symptoms.
We have studied the CNS toxic effects of a rapid i.v. injection of lignocaine 1 mg kg" 1 , and its plasma concentrations, in individuals who had been given diazepam or hyoscine + morphine, or no premedicant drug.
SUBJECTS AND METHODS
Eight healthy anaesthetists (table I) participated in the randomized, cross-over study which had been approved by the Ethics Committee of our institution. None of the subjects had taken any drug known to affect plasma protein binding of local anaesthetic. After fasting for at least 3 h, they were given diazepam 0.14 mg kg" 1 by mouth or hyoscine hydrobromide + morphine hydrochloride (hyoscine 6 (ig kg" 1 and morphine 0. The subjects were studied in a supine position; ECG was monitored continuously and systemic arterial pressure was recorded with an automatic oscillotonometer. A cubital vein and the radial artery (in the arm not used for injecting lignocaine) were cannulated for blood sampling. One hour after premedication, a 2 % lignocaine solution (preservative-free) was injected rapidly (1 ml s" 1 ) in a dose of 1 mg kg" 1 (simulating 30 % of an IVRA dose or an antiarrhythmic dose of lignocaine) into an antecubital vein. Subjective and objective evidence of toxicity were noted by the subject, the observer (investigator) or both. The degree of severity of the CNS symptoms was rated in the order shown in table II (top to bottom). For determination of free and plasma proteinbound concentrations of lignocaine, arterial (0, 1, 2, 5 and 10 min) and venous (0,2, 5,10,20,30 and 60 min) blood samples were drawn. The arterial cannula was removed after the last arterial sample. After centrifugation, the plasma was stored at -20 °C until required for analysis. Lignocaine concentrations were determined by gas chromatography [5] . Unbound lignocaine was separated from plasma using an ultrafiltration method (Amicon Micropartition System). The fraction percentages were corrected (mean correction coefficient 1.14) for the deviation in test temperature (25 °C) and sample pH (7.75-7.80) from physiological values.
Alpha,-acid glycoprotein (AAG) concentrations in plasma from a venous sample obtained immediately before premedication were measured by radial immunodiffusion on M-partigen plates [6] , and by an immunoturbidometric method (Kone Progress, Espoo, Finland) with antiserum and standards from Orion Diagnostica (Espoo, Finland). Albumin concentrations were estimated by an automatic technique with bromocresol green binding [7] . Linear regression analysis was used to evaluate the correlation between the data (number of symptoms, lignocaine plasma concentrations, plasma protein concentrations). Both univariate and multivariate repeated measures analyses of variance (SAS 1985) were performed to test the effects of premedication on plasma concentrations of total and free lignocaine, separately for venous and arterial concentrations. A polynomial transformation was used to test for trends in timedependent measurements. P < 0.05 was considered significant. All values are reported as mean + SEM.
RESULTS

Effect of premedication.
The effect of diazepam was described as mildly sedative and generally pleasant. In all subjects hyoscine-morphine clearly caused marked sedation, drowsiness and dry mouth (but no euphoria), which lasted for several hours after the lignocaine test. (table II) . According to the subjects' reports, the symptoms lasted for 5.0+1.4 min with diazepam (in one subject mild symptoms of lightheadedness persisted for up to 14 min), 2.5±0.3min with hyoscine-morphine and 4.0 + 0.6 min, on average, with no premedication. Although the subjects premedicated with hyoscine plus morphine were all sedated heavily and frequently had trouble controlling their speech, they nevertheless reported CNS symptoms similar to those reported when diazepam or no premedication were given.
There was no correlation between premedica- tion and degree of severity or number of CNS symptoms.
Plasma concentrations of lignocaine, plasma proteins and toxic symptoms. The mean lignocaine plasma concentrations are shown in figure 1 . The highest single arterial plasma concentration was ll.Ougml" 1 , 1 min after injection. The subject with the maximal arterial free lignocaine concentration of 3.3 \ig ml" 1 had symptoms similar to the one with a concentration of 0.8 (ig ml" ECG was normal and systemic arterial pressure remained stable throughout each experiment.
influence acutely induced symptoms of lignocaine toxicity to any measurable extent. Interestingly, despite relatively heavy sedation with hyoscine and morphine, the subjects perceived toxic symptoms surprisingly well. Although anxiety may promote the production of CNS symptoms by local anaesthetics [8] , light or heavy sedation in the participating professional volunteers did not significantly affect the symptoms. Therefore, it may be anticipated that the quality of possible toxic CNS symptoms, for example after an inadvertent intravascular injection in connection with an extradural test dose, is not affected by premedication.
The binding of lignocaine to plasma proteins seems to have little effect on first pass uptake of lignocaine by brain tissue [2] , indicating rapid dissociation of the drug-protein complex during the first transit through the organs.
As a basic drug, lignocaine is bound primarily to the AAG fraction of plasma proteins [9] . Although a small part of the diazepam in the circulation is bound by AAG [9] , albumin is the major binding protein for diazepam, and for the alkaloid morphine [3, 10] . Thus significant exclusion of lignocaine from high-affinity plasma protein binding sites by diazepam or morphine should not be expected. When lignocaine is administered in therapeutic antiarrhythmic doses, approximately 23 % of protein binding in plasma is to albumin [11] . However, albumin has a high binding capacity, and different drugs appear to have different binding sites [3, 12] . In healthy subjects with normal concentrations of albumin, therefore, any measurable pharmacokinetic interaction achieved with relatively modest (albeit therapeutic) concentrations of diazepam or morphine may not occur. The plasma protein fraction which binds hyoscine does not seem to be known. Because of the relatively small dose of hyoscine, a possible protein-binding interaction with lignocaine does not need to be considered.
The lack of correlation between plasma concentrations of lignocaine and toxic symptoms supports the concept that it is the rapidity of exposure of brain cells to local anaesthetics, rather than a defined concentration in blood, that causes CNS symptoms [2, 13] . DISCUSSION Our results indicate that pretreatment with diazepam or with hyoscine + morphine does not
